曲普瑞林联合屈螺酮炔雌醇在子宫腺肌症患者辅助治疗过程中的应用效果探究

目的:探讨曲普瑞林联合屈螺酮炔雌醇在子宫腺肌症患者辅助治疗过程中的应用效果。方法:选取2018年10月至2020年2月我院子宫腺肌症患者96例,依据随机数字表法分为研究组(n=48)及对照组(n=48)。两组均采取左炔诺孕酮宫内节育系统,在此基础上对照组采取屈螺酮炔雌醇,研究组在对照组基础上采取曲普瑞林,均治疗6m。统计两组临床疗效、治疗前及治疗6m后血清生化指标(卵泡雌激素(follicle stimulating hormone,FSH)、黄体生成素(luteinizing hormone,LH)、前列素F-2α(prostaglandin E-2α,PGE-2α)、糖类抗原125(carbohydrate antigen 125,CA125))水平、子宫内膜厚度与子宫体积、痛经程度、月经量、不良反应发生率。结果:研究组总有效率(93.75%)高于对照组(79.17%)(P<0.05)。治疗6m后两组血清FSH、LH、PGE-2α、CA125水平较治疗前降低,且研究组低于对照组(P<0.05)。治疗6m后两组月经量较治疗前减少,VAS分值较治疗前降低,子宫内膜厚度及子宫体积较治疗前缩小,且研究组各项指标改善幅度较对照组更明显(P<0.05)。研究组不良反应发生率(12.50%)与对照组(8.33%)间无显著差异(P>0.05)。结论:联合采取曲普瑞林及屈螺酮炔雌醇治疗子宫腺肌症效果显著,具有安全性。

Application effect of triptorelin combined with drospirone ethinylestradiol in adjuvant treatment of patients with adenomyosis

Objective:To investigate the effect of triptorelin combined with drospirone ethinylestradiol in the adjuvant treatment of patients with adenomyosis.Methods:96 patients with adenomyosis in our hospital from October 2018 to February 2020 were randomly divided into study group(n=48)and control group(n=48).Both groups were treated with levonorgestrel intrauterine contraceptive system.On this basis,the control group was treated with drospirone ethinylestradiol,and the study group was treated with triptorelin on the basis of the control group.Both groups were treated for 6 months.The clinical efficacy,serum biochemical indexesfollicular estrogen(FSH),luteinizing hormone(LH),prostaglandin E-2α(PGE-2α),carbohydrate antigen 125(CA125)]levels,endometrial thickness and uterine volume,dysmenorrhea,menstrual volume and incidence of adverse reactions were statistically analyzed.Results:The total effective rate of the study group(93.75%)was higher than that of the control group(79.17%)(P<0.05);after 6 months of treatment,the serum FSH,LH,PGE-2α,CA125 levels of the two groups were lower than those before treatment,and the study group was lower than the control group(P<0.05);After 6 months of treatment,compared with that before treatment,the menstrual volume of the two groups decreased,the VAS score was lower,the endometrial thickness and uterine volume were reduced;and all the indexes of the study group improved significantly compared with those of the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the study group(12.50%)and the control group(8.33%)(P>0.05).Conclusion:the combination of triptorelin and drospirone ethinylestradiol is effective and safe in the treatment of adenomyosis.